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1. Introduction 
Organ transplantation has saved the lives of thousands of patients beginning from the mid 
1950s. At the end of 2007 the Organ Procurement and Transplantation Network (OPTN) 
database recorded 183,222 people living with a functioning graft in the United States  (Wolfe 
et al., 2010). Over the last two decades survival rates have continued to improve and 
currently 81-91% of kidney transplant recipients and 74-79% of liver transplant recipients 
are alive 5 years post-transplant (Wolfe et al., 2010). This success is a dramatic improvement 
compared to the early era of transplantation and is the result of advances in organ 
preservation, surgical technique, intensive care and immunosuppression. Particularly, the 
development of potent immunosuppressive medications has contributed significantly to the 
success of organ transplantation by reducing the incidence of rejection and graft loss.  In 
recent large studies the incidence of acute rejection is reported as low as 8-15% 1 year after 
kidney transplant (Ekberg et al., 2009) and graft loss due to acute rejection has now become 
very uncommon. 
Clinical immunosuppression after organ transplantation has come a long way over the last 
fifty years. It started with total body irradiation, steroids and azathioprine (see Starzl, 2000 
for a review on the history of immunosuppression).  The rationale behind total body 
irradiation was to control the immune response to the allograft by ablation of the bone 
marrow, a similar principle applied today with the use of depleting agents (see below).  
Other early attempts at controlling the bone marrow and obtain lymphocyte depletion 
included splenectomy, thymectomy and thoracic duct drainage, but these had limited 
success.  Instead, anti-lymphocyte globulin (ALG), prepared from the serum of horses or 
rabbits inoculated with human lymphocytes, was introduced in 1966 with the aim of 
mitigating cellular immunity using heterologous antibodies. (Starzl et al., 1967) 
From the early 1960s to 1980s post-transplant immunosuppression consisted of 
azathioprine, high dose corticosteroids and antilymphocyte globulin.  Cyclosporine was 
introduced in the early 1980s, followed by monoclonal antibodies, then by tacrolimus in the 
1990s and lately by mycophenolic acid and sirolimus (see list below). Immunosuppression 
regimens have changed since the early era of transplantation as a result of the development 
of new drugs. Furthermore, the number of available drugs continues to increase. This article 
will describe the immunosuppressive drugs currently used in clinical transplantation and 
will focus on recent developments. We will also review current organ-specific IMS protocols 
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for kidney, liver, pancreas and intestine transplant to highlight the differences in abdominal 
organ transplantation that require specific immunosuppressive strategies (ie 
immunosuppression in the highly sensitized kidney recipient, prevention of disease 
recurrence after liver transplant, role of induction in intestinal transplantation).  Finally, we 
will highlight current areas of ongoing research and future developments in clinical 
immunosuppression.  
2. Current immunosuppressive agents 
There are several immunosuppressive drugs currently used in different combinations in 
abdominal organ transplantation (see table 1). Most agents target T cell activation and 
proliferation, given the central role of T lymphocytes in organ rejection. Indeed, the control 
of T cell-based mechanisms is key to prevent rejection, especially in the early post-transplant 
period. However, increasing attention is being given to the role of B cells and to the 
production of alloantibodies in late graft injury and chronic rejection. In addition, 
components of the innate immune system (neutrophils, complement) are becoming the 
target for development of new immunosuppressive agents. Here we discuss the 
immunosuppressive agents currently used in clinical transplantation and present new drugs 
being investigated in clinical trials. 
 
Antibodies (monoclonal) 
          Alemtuzumab 
          Basiliximab  
          Daclizumab 
          Muromonab-CD3 (OKT3)  
          Rituximab 
Antibodies (polyclonal) 
          ALG 
          Atgam 
          Thymoglobulin 
Azathioprine 
Calcineurin inhibitors 
          Cyclosporine 
          Tacrolimus 
Corticosteroids 
mTOR inhibitors 
          Everolimus 
          Sirolimus 
Mycophenolic acid 
          Mycophenolate mofetil 
          Mycophenolate sodium 
Others 
          Belatacept 
          Bortezomib 
Table 1. Immunosuppressive drugs currently used in clinical transplantation 
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2.1 Corticosteroids 
Corticosteroids (prednisone, prednisolone, methylprednisolone) were the first 
immunosuppressive drugs to be used in transplantation and remain today first line 
treatment across organs for both prevention and treatment of rejection. The multiple anti-
inflammatory and immunomodulatory effects on a wide variety of cells including 
lymphocytes, granulocytes, macrophages, monocytes and endothelial cells are well known 
and the molecular mechanisms of action of steroids have been described extensively 
(Adcock et al., 2000). Briefly, corticosteroids down regulate cytokine gene expression in 
lymphocytes, antagonize macrophage differentiation, inhibit neutrophil adhesion to 
endothelial cells thereby decreasing their extravasation to the site of inflammation, decrease 
circulating eosinophil and basophil counts, inhibit IgE-dependent release of histamine and 
leukotriene from basophils and inhibit degranulation of mast cells. Additionally, 
glucocorticoids downregulate endothelial cell function including expression of class II MHC 
antigen and expression of adhesion molecules. 
Based on these multiple effects on different cellular components of the immune response 
corticosteroids are very effective in preventing and treating acute allograft rejection. Indeed 
episodes of acute rejection are routinely treated with pulse steroids with generally good 
response, although there are instances of steroid-resistant rejection episodes. 
The multiple side effects of steroids are also well known and include impaired wound 
healing, increased risk of infection, hypertension, weight gain, hyperglycemia, osteoporosis, 
fluid retention, hirsutism, acne and cataracts . Side effects may have an important impact 
especially in the long term and in children (ie growth pattern), therefore multiple trials of 
steroid withdrawal and steroid-free regimens have been designed  in an attempt to limit the 
side effects of corticosteroids, with variable results (see below specific organs).  In addition, 
several steroid withdrawal protocols have been associated with increased acute rejection 
(Knight et al., 2010).  Corticosteroids still maintain a central role in the armamentarium of 
immunosuppressive agents currently available in clinical transplantation. 
2.2 Azathioprine 
Azathioprine was the main immunosuppressive agent, with steroids, for many years in 
clinical transplantation. It is a nucleotide analogue originally developed during research on 
new chemotherapy agents for leukemia. The mechanism of action of azathioprine is to 
incorporate into and to halt DNA replication thus blocking the de-novo purine synthesis in 
lymphocytes. It was originally tested in experimental kidney transplantation in the 1960s 
(Calne et al., 1961) and it obtained improved graft survival with less toxicity compared to 
analogue agents such as 6-mercaptopurine.  Azathioprine is now very rarely used and it has 
been replaced by mycophenolic acid (see below) in many transplant programs.  
2.3 Calcineurin inhibitors 
Calcineurin inhibitors (CNI) are main immunosuppressive agents in use today in virtually 
every transplant program. Cyclosporine and tacrolimus are the two CNI currently used in 
clinical transplantation. Their immunosuppressive effect is to block the production of pro-
inflammatory cytokines including IL-2, INF-γ, TNF-α and to inhibit T cell activation and 
proliferation by inactivating calcineurin, an intracellular calcium/calmodulin phosphatase 
triggered by the engagement of T cell receptor by donor MHC and responsible for de-
phosphorilation of nuclear factor for activated T cells (NF-AT) which promotes the 
transcription of cytokine genes. 
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Although CNI remain the cornerstone of current immunosuppressive protocols, increasing 
attention is being devoted to their long term side effects (ie nephrotoxicity). The impact of 
these side effects and the concomitant introduction of alternative immunosuppressive 
agents led to the design of trials to reduce CNI exposure. Strategies to limit CNI exposure 
include CNI minimization, avoidance, and withdrawal (Flechner SM et al., 2008) However, 
to date trials incorporating mycophenolate mofetil or mTOR inhibitors showed mixed 
results because of adverse events or lack of efficacy (Larson et al., 2006, Ekberg et al., 2007). 
2.3.1 Cyclosporine  
Cyclosporine, a metabolite extracted from the soil fungi Cylindrocarpon lucidum and 
Trichoderma polysporum, initially was investigated as an antifungal but was also shown to be 
immunosuppressive in mice models of skin allotransplantation. Its potent anti-lymphocyte 
properties prolonged the survival of kidney transplants in the dog. The introduction of 
cyclosporine in the early 1980s has revolutionized clinical transplantation and has remained 
the cornerstone of immunosuppression for kidney, liver, heart and other organs for many 
years. The mechanism of action and the immunologic effects of cyclosporine have been 
reported above. With cyclosporine a dramatic increase in early graft survival was observed 
in many centers with some programs reporting almost doubling their 1-year graft survival 
rate from 50% in the late 1970s to 86% in the 1980s (Merion RM et al, 1984). Since the early 
1980s triple immunosuppressive therapy with  cyclosporine, azathioprine and steroids has 
been standard protocol for a long time in many centers and has allowed dramatic growth of 
transplant programs worldwide.  
The main side effects of cyclosporine are nephrotoxicity and hypertension. Other side effects 
include diabetes and cosmetic changes like gingival hyperplasia and hirsutism. With long-
term follow-up, it has become apparent that up to 15% to 20% of patients treated with 
calcineurin inhibitors experience chronic renal insufficiency requiring dialysis and/or renal 
transplantation (Ojo et al., 2003). The nephrotoxicity of cyclosporine is thought to result 
from its vasoconstrictor effects on renal blood vessels. Although early toxicity resulting in 
renal dysfunction may be reversible, the late stages of cyclosporine nephrotoxicity resulting 
in advanced tubular interstitial fibrosis and scarring may be irreversible.  Now cyclosporine 
is used less frequently since other potent immunosuppressive drugs became available (see 
below). 
2.3.2 Tacrolimus 
The introduction of tacrolimus has further improved the remarkable results previously 
obtained with cyclosporine by reducing rejection rates and improving long term graft 
function and survival (Busuttil et al., 2004). 
Tacrolimus (FK506) is a metabolite of the fungus Streptomyces tsukubaensis. The mechanism 
of action of tacrolimus is identical to that of cyclosporine. Upon entering the cytoplasm, it 
binds to an immunophilin referred to as FK-binding protein 12 and inhibits calcineurin, 
preventing the dephosphorylation of the transcription factor NFAT and inhibiting the 
transcription of cytokines necessary for rejection. Tacrolimus has gradually replaced 
cyclosporine in many transplant programs since it was found to be much more potent then 
cyclosporine. Indeed, its first successful use was reported as rescue therapy for rejected liver 
grafts failing conventional therapy (Starzl et al., 1989). Subsequently, tacrolimus has 
gradually been  included in routine immunosuppression protocols in liver transplantation.  
Multicenter trials compared the efficacy and safety of tacrolimus with cyclosporine and 
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showed that tacrolimus was associated with significantly fewer episodes of corticosteroid 
resistant or refractory rejection, although graft survival and patient survival were not 
significantly different; additional findings included a lower incidence of chronic rejection 
and infection. (The U.S. Multicenter FK506 Liver Study Group, 1994; European FK506 
Multicentre Liver Study Group, 1994) 
Since the early 1990s, an increasing number of patients receiving liver, kidney, heart, and 
heart-lung has been successfully immunosuppressed with tacrolimus-based regimens rather 
than cyclosporine. In addition, tacrolimus has made a significant impact on the outcomes of 
intestinal transplantation (see below). As a result, currently many transplant programs 
worldwide have adopted tacrolimus-based immunosuppressive regimens.  However, like 
for cyclosporine, the toxicity profile of tacrolimus has become evident with studies showing 
that the use of tacrolimus is associated with higher risk of diabetes post-transplant and with 
incidence of nephrotoxicity and neurotoxicity comparable or higher than those of 
cyclosporine (Ekberg et al., 2007).  
Tacrolimus is administered twice daily. To improve compliance with the medication a 
modified-release once daily dose form of tacrolimus has been developed  and shown to have 
equivalent systemic exposure of conventional twice-daily tacrolimus (Cross et al., 2007) and 
similar efficacy in preventing kidney (Kramer et al., 2010) and liver (Truneka et al., 2010) 
transplant rejection. 
2.4 Mycophenolic acid 
Mycophenolate mofetil and mycophenolate sodium are similar pro-drugs both converted to 
the active compound mycophenolic acid by liver metabolism and they will be discussed 
together. Mycophenolic acid emerged as a new immunosuppressive agent in the early 1990s 
with a mechanism of action different from CNI (Mele et al., 2000) (Stewart et al., 2001). 
Whereas cyclosporine and tacrolimus both inhibit the enzyme calcineurin and the induction 
of cytokine synthesis soon after T cell activation, mycophenolic acid has no direct effect on 
the production of cytokines but prevents T and B cell proliferation by inhibiting a pathway 
required for cell division. Mycophenolic acid is a selective and noncompetitive inhibitor of 
inosine monophosphate dehydrogenase, which is an important enzyme in the de novo 
pathway of guanine nucleotide synthesis. This results in the inhibition of DNA synthesis in 
T and B lymphocytes thereby inhibiting cell proliferation and function. Other cell types can 
use salvage pathways and are not affected, therefore the effects of mycophenolic acid are 
largely on the immune cells with few effects on the non-immune system. Clinically, 
mycophenolate acid has largely replaced azathioprine because of its fewer myelotoxic and 
hepatotoxic side effects. It is usually combined into a regimen including a calcineurin 
inhibitor and steroids.  
Since the 1990s, when large, double-blind, randomized trials in kidney transplant recipients 
showed the efficacy of mycophenolate acid in preventing early acute rejection in 
combination with cyclosporine and prednisone, this drug has been used widely as a part of 
various combination regimens of immunosuppressive agents. Common mycophenolic acid-
related side effects comprise gastrointestinal symptoms such as abdominal pain, diarrhea 
and nausea, infections (cytomegalovirus) and myelosuppression, namely anemia and 
leucocytopenia, malignancy (post-transplant lymphoproliferative disorders and non 
melanoma skin cancer). 
Mycophenolate sodium is an enteric-coated preparation that allows delayed release of the 
active drug in the small intestine rather than the stomach. This may help alleviate some of 
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the gastrointestinal side effects of mycophenolate mofetil. There is no significant difference 
in rejection and side effects in large randomized trial of mycophenolate mofetil versus 
mycophenolate sodium (Ciancio et al., 2011). The ability of mycophenolic acid to facilitate 
sparing of other immunosuppressive agents, particularly cyclosporine and its related 
nephrotoxicity, is promising. By permitting reduction in cyclosporine doses, mycophenolic 
acid may stabilize or improve renal graft function in patients with cyclosporine-related 
nephrotoxicity or chronic allograft nephropathy. 
2.5 mTOR inhibitors 
The mTOR inhibitors sirolimus and everolimus are among the most recently introduced 
immunosuppressive agents with a mechanism of action different from CNI and from 
antimetabolites.  Sirolimus (or rapamycin) is a macrolide antibiotic, structurally similar to 
tacrolimus, isolated from the fungus  Streptomyces hygroscopicus in 1968 and found to have 
immunosuppressive properties in the late 1980s. Like the calcineurin inhibitors, sirolimus 
acts by binding to an intracellular immunophilin FKB12. This complex sirolimus-
immunophilin inhibits a protein called mammalian target of rapamycin (mTOR). Inhibition 
of mTOR results in selective inhibition of synthesis of new ribosomal proteins which are 
essential for progression of the cells from the G1 to the S phase. This results in blockage of T 
cell activation. In addition, sirolimus has been associated with inhibition of fibroblast 
growth factors required for tissue repair.  This antifibrotic effect has two potentially 
beneficial effects after transplantation in reducing the progression to fibrosis in post liver 
transplant hepatitis C   recurrence (see below) and in reducing the risk of malignancy in 
transplant recipients because of its antiangiogenic effects (Geisler et al., 2010). 
The half life of sirolimus is 60 hours which allows single daily dose unlike other agents 
given twice daily and this has an important impact on patient compliance to 
immunosuppression regimens. Everolimus is a modified form of sirolimus to improve its 
absoprion. Its half life is shorter and is administred twice daily. Everolimus is currently 
undergoing clinical trials in liver transplantation. In addition to being used as 
immunosuppressant, it has been investigated in the treatment of renal cell carcinoma for its 
proliferation signal inhibition and in drug-coated stents to prevent restenosis of coronary 
arteries for its antifibrotic effect (Gabardi et al., 2010)  
There have been a number of studies investigating the impact of adding sirolimus to low 
dose CNI regimens in order to reduce nephrotoxicity of CNI after kidney (Schena et al., 2009), 
liver (Harper et al., 2011) and heart (Raichlin et al., 2007) transplantation. The use of sirolimus 
with mycophenolate mofetil or azathioprine to avoid de novo CNI exposure has improved 
glomerular filtration rate for at least two years in most studies in kidney transplantation with 
comparable incidence of rejection, however experience is limited in liver and heart 
transplantation. However, there have been also reports of an increased risk of nephrotoxicity 
when combining sirolimus with high doses calcineurin inhibitors (Kahan, 2000)   
Sirolimus, unlike calcineurin inhibitors, has been shown to enhance the development and 
function of regulatory T cells, a subset of CD4(+)CD25(+) lymphocytes with the ability to 
suppress alloimmune responses in vitro and in vivo. It is therefore being evaluated as a 
component of strategies to promote tolerance in organ transplant recipients (Knektle 2010). 
In intestinal transplant recipients the introduction of sirolimus in tacrolimus-based regimens 
has significantly delayed the onset and reduced the severity of rejection (see below). 
The adverse effects of sirolimus include thrombocytopenia, leukopenia, anemia, arthralgias, 
hyperlipidemia, pneumonitis, and diarrhea. There have also been reports of wound 
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complications (delayed wound healing, incisional hernia) in the post-transplant period, an 
affect probably secondary to its antiproliferative effects on fibroblasts. Oral ulcers were seen 
with the liquid preparation; however, this seems to be less frequent with the use of the pill 
preparation.  
2.6 Antibodies 
The use of antibodies as part of the immunosuppression regimen post-transplant dates from 
the beginning of clinical transplantation when anti-lymphocyte globulin (ALG) prepared 
from the serum of horses or rabbits inoculated with human lymphocytes was added to 
azathioprine and steroids. In 1986 muromonab CD3, a monoclonal antibody (mAb) 
targeting CD3, was first approved for prevention and treatment of renal allograft rejection.  
Originally, the rationale for the use of antibodies as immunosuppressants was to deplete 
and block the function of immune competent cells. The purified IgG fraction of polyclonal 
antibody preparations is directed against cell-surface molecules expressed on T cells, B cells, 
NK cells and macrophages, causing complement mediated cell lysis, uptake of opsonised 
cells by the reticulo-endothelial system and modulation of surface receptors of lymphocytes. 
Infact the administration of polyclonal antibodies results in profound lymphopenia.  
Polyclonal antibodies are obtained by inoculating rabbits or horses with human 
lymphocytes or thymocytes. Currently available preparations include Thymoglobulin and 
Atgam. Monoclonal antibodies are produced in response to a single antigen. These include 
the mouse monoclonal antibody muromonab (OKT3), which is specific to the CD3 receptor 
and was the first monoclonal antibody to be used in transplantation to treat acute rejection. 
Other monoclonal antibodies include the anti-IL-2 receptor antibodies daclizumab and 
basiliximab, anti CD20 rituximab, antiCD52 alemtuzumab. Other new mAbs are emerging, 
targeting co-stimulatory signals, cell surface receptors and novel protein constructs. 
Antibodies are further classified into lymphocyte-depleting or nondepleting agents (review 
Klipa et al., 2010) The total lymphocyte counts and CD3 counts are usually measured during 
therapy to monitor the achievement of effective depletion and to make dose adjustments in 
case of incomplete depletion.  
Currently, antibodies are administered as induction immunosuppression to the majority of 
kidney, pancreas and intestine transplant recipients in the United States, and less frequently 
to liver recipients. Induction therapy, as opposed to maintenance immunosuppression, 
refers to the use of biological agents and high dose steroids to prevent immune engagement 
and T-cell activation during tissue injury from organ preservation, reperfusion, and 
alloresponse immediately after transplant. The agents most commonly used are 
thymoglobulin and alemtuzumab (depleting) and basiliximab, daclizumab and rituximab 
(non depleting)  (review in Aparna et al., 2009). 
The benefits of induction therapy include a decreased incidence and delayed onset of acute 
rejection, and also delayed introduction of or lowering dose of CNI in the early post-
transplant period allowing for peri-operative renal dysfunction to recover. Other uses of 
antibodies are in desensitization protocols in sensitized kidney transplant recipients (see 
below) and in the treatment of steroid resistant rejection. Rituximab has also been used to 
treat antibody-mediated rejection in kidney transplant (Kaposztas et al., 2009). In addition to 
considerable cost, side effects include cytokine release phenomena secondary to cytolysis 
and characterized by fevers, chills, hypotension. Other side effects are nausea, diarrhea, 
arthralgias, thrombocytopenia, dyspnea, and seizures. The risk of infection and of 
posttransplantation lymphoproliferative disease is increased with antibody therapy. 
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2.7 New immunosuppressive drugs 
Different pathways and stages of the immunologic response are the target of strategies to 
develop new immunosuppressive drugs: cell-surface molecules, signaling mechanisms, T-
cell proliferation, cell trafficking and cell recruitment. 
New immunosuppressive drugs include mainly proteins targeting T-cell and B-cell surface 
receptors and non-protein drugs (also called small molecules) targeting intracellular pathways. 
Belatacept is a fusion protein composed of the Fc fragment of a human IgG1 
immunoglobulin linked to the extracellular domain of CTLA-4. (review Weclawiak et al., 
2010)  It represents a new class of immunosuppressants. Unlike calcineurin inhibitors that 
block or diminish the effects of T-cell activation on allografts, belatacept prevents T-cell 
activation by selectively blocking T-cell costimulation molecules. In the initial trial in kidney 
transplant recipients it was as effective as cyclosporine in preventing acute rejection but 
with better preservation of kidney function and reduction of chronic allograft nephropathy 
(Vincenti et al., 2005) The stability of graft function and the safety profile of belatacept at 5 
years has been reported in a subsequent study (Vincenti et al., 2010).  
Memory T cells play a crucial role in acute and chronic rejection and are a potent barrier to 
transplantation tolerance. Alefacept, a fusion protein combining Leukocyte Function 
associated Antigen-3 (LFA3) with IgG currently approved for psoriasis, binds to CD2 on T 
cells (Ellis et al, 2001). Unlike belatacept that prevents activation of naïve T cells, alefacept 
targets memory T cells (Weaver et al., 2008) since CD2 is espressed more on memory than 
naïve T cells. 
Efalizumab (Dedrick et al., 2002) is a humanized antiCD11a (LFA1) monoclonal antibody 
used in patients with chronic plaque psoriasis (Kuschei et al., 2011). It blocks the binding of 
LFA1 to intracellular adhesion molecule-1 (ICAM-1) causing loss of activation, adhesion and 
migration of T-cells. Preliminary experience with efalizumab in kidney transplantation 
showed efficacy in controlling rejection but raised concern of overimmunosuppression since 
8% of patients developed post-transplant lymphoproliferative disease (Vincenti et al., 2007). 
New non-protein drugs (also identified as small molecules) target intracellular pathways of 
the immune response to the allograft, such as Janus kinase proteins (JAK), which mediate 
signal transmission between cell membrane receptors and the nucleus.  The 
immunosuppressive effect of inhibition of JAK3 results from blocking the signaling of the 
gamma chain subfamily of cytokines (interleukins 2, 4, 7, 9, 15 and 21). Tofacitinib, a Janus 
kinase 1/3 inhibitor developed for the treatment of rheumatoid arthritis (Flanagan et al., 
2010) prolonged kidney allograft survival in cynomolgus monkeys without concomitant use 
of calcineurin inhibitor (Borie et al., 2005). In clinical kidney transplantation it has been used 
in a calcineurin inhibitor- free regimen (Busque et al., 2009). This study reported comparable 
acute rejection rates between tofacitinib and tacrolimus-based immunosuppression but 
raised concern of overimmunosuppression in the form of increased BK virus infection rates. 
Two new other biologic agents being developed are 4D11, a costimulation blockade agent 
targeting CD40 (Aoyagi et al., 2009) and natalizumab, a humanized IgG4 approved for 
multiple sclerosis and Crohn’s disease targeting alpha4 submunit of integrins thus 
inhibiting leucocyte adhesion (Hutchinson 2010). 
Voclosporine (ISA247) is a novel oral semisynthetic structural analogue of cyclosporine that 
has been modified at the first amino acid residue of the molecule. This drug has been shown 
to be more potent than cyclosporine in vitro and in vivo in rat heterotopic heart 
transplantation. The advantage of this cyclosporine-analogue drug is the lack of 
nephrotoxicity. There is still limited experience with this drug in clinical transplantation. 
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Preliminary results show non-inferiority to tacrolimus in preventing rejection (Gaber et al., 
2008). More data is needed on the efficacy and safety profile in the long term.  
Protein kinases (PKC) play a key role in signaling pathways downstream of the T-cell 
receptor (signal 1) and CD28 (signal 2) and thereby are involved in early T-cell activation. 
There are several isoforms of PKC. PKCh is largely restricted toT lymphocytes and mediates 
activation of the transcription factors activator protein-1 and nuclear factor (NF) jB, leading 
to downstream IL-2 production. The PKCh knockout mice demonstrate impaired T-cell 
activation. Sotrastaurin (AEB071) is a new oral low molecular weight compound that 
effectively blocks early T-cell activation by selective inhibition of PKC and therefore has a 
different mechanism of action from that of the CNIs. (Kovarik et al., 2011) 
In kidney transplantation the deleterious effects of the humoral (antibody-mediated) 
component of acute rejection and their impact on long term graft survival are being 
increasingly recognized. This has prompted the development of more targeted antihumoral 
therapies. Bortezomib is an antineoplastic agent originally developed for the treatment of 
multiple myeloma. It is a proteasome inhibitor that induces apoptosis in rapidly dividing 
cells with active protein synthesis like plasma cells. In kidney transplantation it has been 
reported to revert antibody-mediated rejection (Perry et al., 2009, Walsh et al., 2010). Early 
antibody-mediated rejection demonstrated increased response to proteasome inhibitors than 
late AMR (Walsh et al.,2011) 
3. Immunosuppression in kidney transplantation 
Kidney transplant is the most frequently performed among abdominal organ transplants 
and in 2010 16,896 patients received a kidney transplant in the United States, 37% of which 
were from live donor. (unos) (http://optn.transplant.hrsa.gov/latestData/rptData.asp). The 
advantages of live-donor versus deceased donor kidney transplant are multiple including 
shorter time on the waiting list, shorter cold ischemia time (ie the interval between organ 
procurement and transplantantation), less preservation injury and overall better graft 
function in the short and long term. However, the immunologic risk in live-donor kidney 
transplant is not inferior to deceased donor, even in case of live-related donor (ie between 
non-identical siblings). On the contrary, live donor kidney transplant is becoming a bigger 
immunological challenge than deceased donor with the increasing number of transplants 
performed in highly sensitized or ABO incompatible recipients (see below). 
There are several immunosuppression protocols currently used in kidney transplantation, 
but the majority include induction with depleting or non-depleting antibodies and 
maintenance immunosuppression based on a combination of agents (usually triple therapy) 
including CNI, mycophenolic acid, sirolimus and steroids. 
Current acute rejection rate is 10-15% (Gaston et al., 2009) and usually the function of the 
graft is maintained after treatment of the rejection episode. Immunosuppression regimens 
currently available are very effective in treating episodes of acute rejection so that graft loss 
due to acute rejection has now become a rare event. Instead, chronic rejection (or chronic 
allograft nephropathy) remains a major cause of graft loss, usually a late event (years) after 
transplant. The causes of chronic allograft nephropathy and graft loss are multiple including 
repeated episodes of rejection, disease recurrence, CNI toxicity and others. Indeed, one of 
the main side effects of CNI is nephrotoxicity, affecting up to 16% of non-renal transplant 
recipients at 3 years and resulting in end stage kidney disease requiring dialysis in 5-20% of 
patients 5 years after transplant (Ojo et al.,2003). This prompted the design of several trials 
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of CNI withdrawal, minimization or avoidance in an attempt to limit the impact of CNI 
nephrotoxicity. However, CNI cannot be avoided completely in kidney transplantation 
without paying the price of high rejection rate up to 53%  within the first year (Vincenti et 
al., 2001). So another approach would be to reduce CNI (Ekberg et al., 2007). 
Increasing attention is being recently devoted to the role of late antibody mediated rejection 
causing chronic sub-acute immune mediated injury.  Chronic antibody mediated injury is 
being recognized as a cause of late graft loss and is a process that is not controlled by CNI or 
other current drugs (Colvin 2010, Kirk et al., 2010). 
Highly sensitized and ABO-incompatible recipients  
Immunologic sensitization in a transplant candidate refers to the presence of pre-formed 
antibodies and it is measured as PRA (Panel of Reactive Antibodies), which express the 
percentage of the antigenic repertoire in the general population to which the transplant 
candidate has developed antibodies (0-100%). The causes of sensitization are multiple and 
include blood transfusions, previous transplant, pregnancies and infections. Highly 
sensitized patients have PRA of 80% or higher. These patients are at greater risk of rejection 
and graft loss than non-sensitized patients. In addition, highly sensitized patients are likely 
to wait longer for a 0-mismatch kidney graft than non-sensitized patients. This has 
prompted the development of desensitization protocols to enable highly sensitized patients 
to receive a successful transplant in a timely manner.  The aim of desensitization protocols is 
to reduce the amount of circulating HLA antibodies and to prevent the formation of new 
antibodies.  Strategies currently adopted to achieve these goals include plasmapheresis to 
remove HLA antibodies, intravenous immunoglobulins (IvIg) to neutralize circulating 
antibodies and to inhibit complement activation, rituximab (a chimeric anti CD20 
monoclonal antibody) to deplet B cells and, more recently, bortezomib, a proteasome 
inhibitor that targets plasma cells (see above). The protocol at our Institute also includes 
mycophenolate sodium started the week before transplant as part of the strategy to control 
the B cell component of the immune response (Melancon et al., 2011)  Current results of 
desensitization programs demonstrate graft function and graft survival comparable to non-
sensitized patients (Montgomery et al., 2010, Melancon et al., 2011, Niederhaus et al., 2011). 
Until recently, another barrier to a successful kidney transplant has been ABO-
incompatibility between donor and recipient (ie donor blood type is A or B and recipient 
blood type is O). Over the last decade this barrier has been overcome in some transplant 
centers by the implementation of programs of paired kidney exchange and antibody 
reduction therapies in which a number of donor-recipient pairs are entered into a pool and 
matched according to blood type compatibility (Montgomery et al., 2006) (Melancon et al., 
2011). In addition to entering an exchange program, the recipient of an ABO incompatible 
pair with high isohemoagglutinin titers can also be treated with plasmapheresis and anti-B 
cell agents to reduce the isohemoagglutinin titer to 1:16 or below, a level considered safe to 
proceed with ABO incompatible transplant. Since the number of kidneys from deceased 
donors remains inadequate, living kidney donation has allowed for more patients to be 
removed from the waiting list. Programs of paired kidney exchange and the implementation 
of antibody reduction therapies have allowed the use of ABO incompatible donors and also 
the inclusion of non-directed good Samaritan donors, who enter the system with a desire to 
donate a kidney to someone for purely altruistic purposes. These strategies have all 
contributed to magnify the opportunities for a successful transplant for patients who 
otherwise would have had to wait 5-7 years for a matched kidney from deceased donor. In 
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our recent series, all patients received a transplant within 90 days of their initial evaluation 
for living donor transplantation (Melancon et al., 2011). 
4. Immunosuppression in liver transplantation 
Liver transplantation has become an established treatment for patients with decompensated 
cirrhosis and acute liver failure and today the liver is the second most commonly performed  
abdominal organ transplant. Currently, 6,000 liver transplants are performed in the US yearly 
(unos). (http://optn.transplant.hrsa.gov/ar2009/Chapter_IV_AR_CD.htm?cp=5#TOC). 
In parallel to the success of kidney transplantation, the outcomes of liver transplantation 
have continued to improve over the last two decades following better surgical techniques 
and the introduction of more potent immunosuppression. The introduction of cyclosporine 
first and later tacrolimus has allowed to control the rejection rate and prolong allograft 
survival ((Starzl et al., 1985, Busuttil et al., 2004). Especially tacrolimus has played an 
important role in liver transplantation since its introduction by allowing to rescue grafts 
from cyclosporine resistant rejection (Starzl et al., 1989). As a result, cyclosporine is less 
commonly used today in liver transplantation and most immunosuppression protocols are 
based on tacrolimus, associated to mycophenolic acid and steroids (reviewed in Geissler et 
al., 2009 and Pillai et al., 2009). 
Usually liver transplant recipients do not receive antibody-based induction 
immunosuppression. Rather, high-dose methylprednisolone (500 mg – 1 g ) is given 
intravenously as induction at the time of implantation of the liver and rapidly tapered from 
the time of surgery to a daily maintenance dose of 5 to 10 mg per day. Many programs taper 
and discontinue prednisone at 3 to 6 months to avoid the side effects of long-term 
prednisone use. Prednisone cessation does not seem to have a negative impact on graft 
function. Indeed, steroid withdrawal trials have demonstrated that corticosteroid-free 
regimens do not lead to increased rejection rates. However, in patients transplanted for 
immune-mediated liver disease such as primary biliary cirrhosis, primary sclerosing 
cholangitis and autoimmune hepatitis it seems prudent to maintain prednisone therapy in 
the long term, albeit at a low-dose, in order to reduce the risk of disease recurrence.  
Corticosteroids are also used in the treatment of episodes of acute cellular rejection: 
intravenous methylprednisolone is usually given at a dose of 1,000 mg on alternate days for 
a total of 3 doses, followed by taper.  
Acute rejection does not impact on graft function in the long term in the vast majority of 
cases given the resilience and the regenerative capacity of the liver as opposed to kidney or 
other solid organs. 
An important issue in immunosuppression in liver transplant recipients is the prevention of 
nephrotoxicity associated with CNI. Chronic renal damage is affecting up to 16% of non-
renal transplant recipients treated with CNI (Ojo et al., 2003) and the search for the best 
renal sparing immunosuppression strategy in liver transplantation is still ongoing. A key 
factor seems to be the tailoring of the immunosuppression regimen to the individual patient. 
In patients with renal insufficiency at the time of transplant one strategy is to hold 
calcineurin inhibitors and to use an IL-2 receptor blocker as induction agent. This will obtain 
effective immunosuppression early post-transplant allowing the introduction of CNI to be 
delayed until after resolution of peri-operative renal dysfunction. In the event of non-
recovery of renal function, the addition of sirolimus may be considered. A number of 
studies have reported on the use of sirolimus in patients with renal insufficiency after liver 
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transplantation and especially in those with calcineurin inhibitor (CNI)-associated 
nephrotoxicity. The results of these studies have not been conclusive. A recent meta-analysis  
showed that conversion to sirolimus from CNIs in LT recipients with renal insufficiency 
[glomerular filtration rate (GFR) < 60 mL/minute or creatinine level ≥ 1.5 mg/dL] is 
associated with a non-significant improvement in renal function. In addition, although 
patient and graft survival were not significantly different, infections, ulcers and 
discontinuation of therapy were significantly more common in patients treated with 
sirolimus compared to control (Asrani et al., 2010). This adds to an earlier concern raised by 
previous randomized studies when sirolimus was first tried in liver transplantation in 1999. 
One study (Wiesner et al 2002) reported increased risk of hepatic artery thrombosis and 
death compared to standard immunosuppression. This study was interrupted and led the 
FDA to issue an alert on the use of sirolimus in liver transplant. 
(http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsan
dProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165015.htm).  
However, sirolimus is currently being used by transplant programs in selected patients. A 
recent single center retrospective study on 148 patients converted to sirolimus at any time 
post-transplant for renal function impairment or for progression of fibrosis in HCV positive 
recipients documents that sirolimus was safe and effective with low rejection rates (3.4%) 
and no cases of hepatic artery thrombosis (Harper et al., 2011). Another large single center 
retrospective study reported on the safety and efficacy of sirolimus in liver transplant with 
lower incidence of rejection and similar survival rates compared to other regimens 
(Campsen et al., 2011).  
Finally, other recent studies have reported that the antifibrotic and antiangiogenic effects of 
sirolimus may have a favorable impact in HCV positive recipients and patients transplanted 
for hepatocellular carcinoma, respectively (see below). 
A special consideration has been given over the last few years to immunosuppression 
regimens used in HCV positive liver transplant recipients. HCV-related cirrhosis is now the 
most common indication for liver transplantation in the US and HCV recurrence in the graft 
is a major risk factor for graft loss. To date there is no single best strategy to successfully 
prevent HCV recurrence post-transplant, although new antivirals are being developed that 
may have a positive impact. The management of immunosuppression in HCV liver 
transplant recipients has been the focus of several studies but consensus on the best 
immunosuppression regimen in HCV recipients is lacking. However, it seems to be now 
accepted in many centers that the use of steroids, especially high-dose intravenous boluses 
to treat acute cellular rejection should be considered very carefully in patients with hepatitis 
C because of the risk of severe recurrence of hepatitis C.  (Berenguer 2011). Therefore, the 
prevention of rejection by obtaining and maintaining adequate levels of tacrolimus from the 
very early post-operative period is very important. Cyclosporine has been suggested to be 
superior to tacrolimus in controlling HCV recurrence post-transplant given the antiviral 
effects of cyclosporine in vitro but clinical trials failed to confirm this expectation and 
currently there is no evidence that the choice of CNI (cyclosporine or tacrolimus) makes a 
significant difference in outcome in HCV recipients (Berenguer et al., 2010). Antiviral 
therapy with interferon and ribavirin is an option in selected transplant recipients with 
recurrent HCV: progression to cirrhosis is slower, risk of graft decompensation is lower and 
patient survival is longer in responders to antiviral treatment compared to non-responders 
(Berenguer et al., 2008). However, the pro-inflammatory effects of interferon increase the 
risk of acute rejection, chronic rejection and de-novo autoimmune hepatitis post-transplant 
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(Nazia et al., 2011). Pre-transplant antiviral treatment is poorly tolerated in Child C patients 
(Melero et al., 2009).  
The antifibrotic effect of sirolimus has been considered to have a potential impact on 
slowing down fibrosis progression in HCV-positive recipients (Wagner et al., 2010). A recent 
study on 88 patients treated with sirolimus-based immunosuppression reports that, 
although timing or severity of post-transplant HCV recurrence were not affected, hepatitis 
activity and fibrosis scores were lower on serial biopsy compared to conventional 
immunosuppression regimens (Asthana et al., 2011). Further studies will have to confirm 
the role of sirolimus in HCV-infected grafts. 
Liver transplantation is the most radical and successful treatment for selected patients with 
hepatocellular carcinoma (HCC) who fulfill transplant criteria. Tumor recurrence affects 10-
20% of patients within 2 years after transplant and is a major determinant of patient 
survival. Multiple factors determine the risk of recurrence of HCC after liver transplant, 
including staging and biologic aggressivity of HCC. Post-transplant immunosuppression 
increases the risk of tumor recurrence and the choice of the immunosuppression regimen 
may have an impact on outcomes. Drugs like mTOR inhibitors (sirolimus, see above) 
effectively reduce cell growth and angiogenesis in animal models of hepatocellular cancer 
(review in Treiber 2009) and may have a role in reducing the risk of recurrence in patients 
transplanted for HCC. In a recent study patients transplanted for HCC and treated with 
sirolimus had lower recurrence rates than patients treated with tacrolimus (Chinnakotla et 
al., 2009); a subsequent study on registry data confirmed better survival rates in sirolimus 
patients compared to non-sirolimus (Toso et al., 2010). 
New drugs are being developed for the treatment of HCC. Sorafenib is a tyrosine kinase 
inhibitor shown to increase survival in patients with advanced HCC (Llovet et al., 2008). 
Trials are ongoing on the use of sorafenib to prevent recurrence after transplant (Villanueva 
et al., 2011). 
Currently, antibodies are not commonly used in liver transplantation. OKT3 has been in the 
past the most commonly used monoclonal antibody in liver transplantation. It was 
originally introduced in 1987 for prophylaxis of acute cellular rejection but now it is mainly 
used in patients with steroid-resistant cellular rejection. The use of OKT3 and of other 
depleting agents is associated with early and severe recurrences of hepatitis C and must be 
used with caution in this cohort of patients. (Rosen et al., 1997, Eghtesad et al., 2005) 
Two non-depleting IL-2 receptor antibodies, daclizumab and basiliximab, are being used in 
liver transplantation for induction immunosuppression in patients with renal failure to 
allow a delayed introduction of CNI (Verna et al., 2011).   
Alemtuzumab has been used in tolerance inducing protocols in liver transplantation but is 
not currently used outside research protocols (Weissenbacher et al., 2010). 
5. Immunosuppression in pancreas transplantation 
Currently about 1,100 patients receive a pancreas transplant in the US per year. The main 
indication is to restore normoglycemia in patients with type I diabetes on high insulin 
regimens to improve or at least to arrest the progression of diabetic nephropathy, 
retinopathy and neuropathy. The advantages of pancreas transplant versus insulin therapy 
in obtaining normoglycemia have been well documented (Gremizzi et al., 2010). 
Hypoglycemia unawareness, a complication of insulin therapy, is also an indication for 
pancreas transplant. Since the year 2000 islet cell transplant has been introduced as an 
alternative less invasive treatment for diabetes (Shapiro et al., 2000) with reports of variable 
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success over the years (review in (de Kort et al., 2011)). The long term function of 
transplanted islets remains an unresolved issue. Recent studies report that pancreas 
transplant obtains higher rates of and longer lasting insulin independence compared to islet 
cell transplant, but with higher risk of surgical complications (Vardanyan et al., 2010, Maffi 
et al., 2011). The immunological aspects and immunosuppression regimens specific to islet 
transplant have been extensively reviewed (Azzi et al., 2010) and will not be discussed here.  
The pancreas is transplanted either simultaneously with the kidney for patients with renal 
failure due to type 1 diabetes mellitus or as isolated pancreas. In addition, the pancreas is 
included in the multivisceral graft for selected patients transplanted for intestinal failure 
(see below). Advances in surgical techniques and immunosuppression management have 
obtained current pancreas graft survival rates of 86% at 1 year, between 60 and 80% at 3 
years and 53% at  10 years, respectively (Gruessner et al., 2010).  
Most pancreas transplant recipients receive induction therapy with T-cell-depleting agents 
thymoglobulin or alemtuzumab and maintenance immunosuppression with a combination 
of CNI (mostly tacrolimus), mycophenolate mofetil, sirolimus and rapid steroid withdrawal 
(review in Heilman et al., 2010). The incidence of acute rejection after pancreas transplant is 
reported between 20 and 35% at 3 years (Farney et al., 2009). Like in kidney transplant, the 
combination of sirolimus with full dose CNI may accentuate nephrotoxicity. There have 
been trials of elimination of CNI to avoid nephrotoxicity with similar patient and graft 
survival at 6 months compared to tacrolimus based regimens, but with higher rates of acute 
rejection (Gruessner et al 2005). Over the last years, more and more maintenance protocols 
have avoided the use of steroids (Knight et al., 2010). 
6. Immunosuppression in intestinal transplantation 
Intestinal transplantation is the newest and most recently developed among abdominal 
organ transplants. Although it has been attempted experimentally for decades since the 
pioneering work of Lillehei (Lillehei et al 1959), the first successful intestinal transplant in 
humans was reported in 1990 (Grant et al., 1990). Over the last decade intestinal 
transplantation has become clinically established as an effective treatment  for patients with 
intestinal failure and life-threatening complications of parenteral nutrition (Fishbein 2009). 
In recent years 150-180 intestinal transplants are performed in US per year. (unos) 
http://optn.transplant.hrsa.gov/latestData/rptData.asp 
Rejection has been a formidable obstacle to successful intestinal transplantation. The 
development of effective immunosuppression together with advanced surgical techniques 
and improved patient management have significantly contributed to the success of intestinal 
transplantation. Although initially rejection and mortality rates were high, the outcomes of 
intestinal transplantation have markedly improved over the last decade and now survival 
rates are close to other solid organ transplants. However, still transplantation of the intestine 
remains a greater immunologic challenge compared to other solid organs. The high 
immunogenicity of the intestinal graft is related to its rich composition in lymphoid tissue 
(80% of the body immune cells reside in the gut) and also to the presence of a complex 
innate immune system continuously exposed to intraluminal foreign antigens and microbes. 
A delicate and fine balance between absorption of nutrients and defense from infection is 
regulated at the level of the intestinal surface and the interplay between innate and acquired 
components of the immune response at the level of the intestinal mucosa is being better 
understood in recent years (see below). 
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The introduction of tacrolimus in the early 1990 and induction immunotherapy (Reyes et al 
2005) have decreased the rejection rate from historical rates of 80 or more to 20-40% in most 
recent series. Episodes of acute rejection are treated with  intravenous pulse steroids and/or 
thymoglobulin, depending on severity. The severity of rejection episodes has been better 
controlled with the introduction of sirolimus in addition to tacrolimus-based maintenance 
immunosuppression (Fishbein et al., 2002, Gupta et al., 2005). Infliximab, an anti-tumor 
necrosis factor alpha antibody used for Crohn’s disease, has been successful in isolated cases 
as salvage therapy in patients with thymoglobulin resistant rejection (De Greef et al., 2011).  
Immunosuppression protocols continue to evolve (Abu-Elmagd et al., 2009, Pirenne  et al., 
2009) and different drug combinations are used with the cornerstone for maintenance 
immunosuppression being tacrolimus.  
New insight in intestine transplant function and on new strategies to control allograft 
rejection comes from studies on gut microflora and innate immunity. The normal intestinal 
flora is dominated by anaerobic species Bacteroides and Clostridia.  Post-transplant the 
composition of the gut microflora changes and the microbial community is dominated by 
Lactobacilli and Enterobacteria, which are facultative anaerobes (Hartman et al., 2009). This 
represents an inversion of the normal flora. After surgical closure of the ileostomy, which is 
usually undertaken three months post-transplant, the microbial community reverts to the 
normal flora. Therefore, the transplanted intestine can function with either of two alternate 
microbial populations. As in patients with inflammatory bowel disease, the functional 
impact of alterations in the gut microflora is only recently being recognized and may have 
implications for the management of intestinal transplant rejection.  
The nucleotide-binding oligomerization domain 2 (NOD2) is an intracellular sensor for 
pathogen/microbe associated molecular patterns that recognizes a component of the 
bacterial cell wall. NOD2 protein is a critical regulator of bacterial immunity in the intestine 
and is required for the expression of intestinal anti-microbial peptides. Mutations of NOD2 
are highly correlated with Crohn’s disease.  We found that 35% of intestinal transplant 
recipients have NOD2 mutations associated with Crohn’s disease and that the risk severe 
rejection and of graft failure were significantly greater in the NOD2 mutant recipients 
compared with the NOD2 wild-type recipients (Fishbein et al 2008). The presence of a 
NOD2 polymorphism in the recipient may influence the viability of the allograft by 
interrupting NOD2- dependent circuits required to maintain intestinal homeostasis with 
respect to commensal flora: a recipient lacking a functional intestinal microbial-sensing 
system may be more exposed to allograft damage secondary to rejection than a recipient 
with an intact system. 
7. Future perspectives 
Renal function impairment, opportunistic infections (Cytomegalovirus, Epstein-Barr related 
post-transplant lymphoproliferative disease and others) and metabolic disorders (diabetes 
and others) are frequent complications of prolonged immunosuppression and remain a 
major challenge to improve the long term outcomes of transplant recipients.  Future 
strategies to limit the impact of these complications include the development of new non-
nephrotoxic agents, the individualization of organ-specific immunosuppression regimens 
tailored to patient needs and the design of protocols of minimization of immunosuppression 
and tolerance induction. Studies on gene expression profiling and other methods derived 
from the –omics approach will further contribute to characterize the rejection process and to 
monitor the immune response.    
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The role of B cells and antibodies is increasingly being investigated and recognized as a 
target for treatment. The presence and persistence of donor-specific antibodies in the long 
term follow-up of kidney transplant recipients led to the recognition that chronic antibody 
mediated injury may be responsible for late graft loss. (Colvin 2010). This has prompted 
interest in new B-cell based therapeutic strategies and trials are under way involving agents 
to control humoral immunity. 
The contribution of memory T cells (Lo et al., 2011) and of systemic complement activation 
(Damman et al., 2011) to the rejection process  will also be better characterized by ongoing 
trials. 
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